DE60209251D1 - Adenosine a2a receptor antagonisten - Google Patents
Adenosine a2a receptor antagonistenInfo
- Publication number
- DE60209251D1 DE60209251D1 DE60209251T DE60209251T DE60209251D1 DE 60209251 D1 DE60209251 D1 DE 60209251D1 DE 60209251 T DE60209251 T DE 60209251T DE 60209251 T DE60209251 T DE 60209251T DE 60209251 D1 DE60209251 D1 DE 60209251D1
- Authority
- DE
- Germany
- Prior art keywords
- adenosine
- receptor antagonists
- antagonists
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33429301P | 2001-11-30 | 2001-11-30 | |
| US334293P | 2001-11-30 | ||
| PCT/US2002/038134 WO2003048164A2 (en) | 2001-11-30 | 2002-11-26 | Adenosine a2a receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60209251D1 true DE60209251D1 (de) | 2006-04-20 |
| DE60209251T2 DE60209251T2 (de) | 2006-11-09 |
Family
ID=23306533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60209251T Expired - Lifetime DE60209251T2 (de) | 2001-11-30 | 2002-11-26 | Adenosine a2a receptor antagonisten |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7041666B2 (de) |
| EP (1) | EP1453835B1 (de) |
| JP (2) | JP4284181B2 (de) |
| KR (1) | KR20050044607A (de) |
| CN (1) | CN1596258A (de) |
| AR (1) | AR038366A1 (de) |
| AT (1) | ATE317844T1 (de) |
| AU (1) | AU2002346572A1 (de) |
| CA (1) | CA2468681C (de) |
| DE (1) | DE60209251T2 (de) |
| ES (1) | ES2258164T3 (de) |
| HK (1) | HK1064100A1 (de) |
| HU (1) | HUP0402270A3 (de) |
| IL (1) | IL161572A0 (de) |
| MX (1) | MXPA04005156A (de) |
| PE (1) | PE20030739A1 (de) |
| TW (1) | TW200300686A (de) |
| WO (1) | WO2003048164A2 (de) |
| ZA (1) | ZA200404160B (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1544200A1 (de) * | 2002-09-24 | 2005-06-22 | Kyowa Hakko Kogyo Co., Ltd. | 1,2,4-TRIAZOLO 1,5-c PYRIMIDINDERIVAT |
| ATE490775T1 (de) | 2002-12-19 | 2010-12-15 | Schering Corp | Verwendung von a2a rezeptor-antagonisten zur behandlung des extrapyramidalen syndroms |
| US20060106040A1 (en) | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| WO2004092172A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists |
| US7816353B2 (en) * | 2003-10-24 | 2010-10-19 | Exelixis, Inc. | P70S6 kinase modulators and method of use |
| AR050926A1 (es) * | 2004-09-03 | 2006-12-06 | Astrazeneca Ab | Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac) |
| JPWO2006129626A1 (ja) * | 2005-05-30 | 2009-01-08 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法 |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| CN101679367A (zh) * | 2007-05-24 | 2010-03-24 | 田边三菱制药株式会社 | 脑梗塞治疗药剂 |
| MX2009013897A (es) * | 2007-06-25 | 2010-03-30 | Neurogen Corp | Piperacinil oxoalquil tetrahidro-beta-carbolinas y analogos relacionados. |
| US20100093764A1 (en) * | 2008-10-13 | 2010-04-15 | Devraj Chakravarty | AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| US20100093756A1 (en) * | 2008-10-13 | 2010-04-15 | Berbay J Kent | HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2010061696A1 (ja) | 2008-11-25 | 2010-06-03 | 日産自動車株式会社 | 導電部材及びこれを用いた固体高分子形燃料電池 |
| WO2010126811A1 (en) * | 2009-04-27 | 2010-11-04 | Boehringer Ingelheim International Gmbh | Cxcr3 receptor antagonists |
| US8952004B2 (en) | 2010-01-07 | 2015-02-10 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
| CA2812378C (en) * | 2010-09-24 | 2016-11-29 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
| WO2012127472A1 (en) * | 2011-03-22 | 2012-09-27 | Mapi Pharma Ltd. | Process and intermediates for the preparation of preladenant and related compounds |
| CN110446712B (zh) * | 2017-04-07 | 2021-09-14 | 南京明德新药研发有限公司 | 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物 |
| KR20200139153A (ko) | 2018-02-27 | 2020-12-11 | 인사이트 코포레이션 | A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘 |
| WO2019206336A1 (zh) * | 2018-04-28 | 2019-10-31 | 南京明德新药研发有限公司 | 一种三唑并嘧啶类化合物的晶型、盐型及其制备方法 |
| CA3100731A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GEP20237560B (en) | 2018-07-05 | 2023-10-25 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
| AR116315A1 (es) | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | Compuestos de triazolo-pirimidina y usos de los mismos |
| EP3883576A4 (de) * | 2018-11-20 | 2022-06-22 | Merck Sharp & Dohme Corp. | Substituierte aminotriazolopyrimidine und amino-triazolopyrazin-adenosinrezeptor-antagonisten, pharmazeutische zusammensetzungen und deren verwendung |
| CA3119774A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| JOP20210117A1 (ar) | 2018-11-30 | 2023-01-30 | Merck Sharp & Dohme | مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها |
| CA3124088A1 (en) | 2018-12-20 | 2020-06-25 | Incyte Corporation | Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 |
| WO2020128036A1 (en) * | 2018-12-21 | 2020-06-25 | Ryvu Therapeutics S.A. | Modulators of the adenosine a2a receptor |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU622330B2 (en) | 1989-06-23 | 1992-04-02 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides |
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| DE69428977T2 (de) | 1993-07-27 | 2002-07-11 | Kyowa Hakko Kogyo Co., Ltd. | Arzneimittel gegen Parkinsonsche Krankheit |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| JP4195729B2 (ja) | 1997-03-24 | 2008-12-10 | 協和醗酵工業株式会社 | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| NZ510629A (en) * | 1998-09-22 | 2003-04-29 | Kyowa Hakko Kogyo Kk | [1,2,4]Triazolo[1,5-c]pyrimidine derivatives and pharmaceutical use as adenosine A2A receptor antagonists |
| IL152726A0 (en) | 2000-05-26 | 2003-06-24 | Schering Corp | Adenosine a2a receptor antagonists |
| JPWO2002079204A1 (ja) * | 2001-03-28 | 2004-07-22 | 協和醗酵工業株式会社 | ８−チアゾリル［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体 |
| HUP0402324A3 (en) | 2001-11-30 | 2008-09-29 | Schering Corp | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them |
-
2002
- 2002-11-25 PE PE2002001128A patent/PE20030739A1/es not_active Application Discontinuation
- 2002-11-25 TW TW091134178A patent/TW200300686A/zh unknown
- 2002-11-25 AR ARP020104528A patent/AR038366A1/es unknown
- 2002-11-26 DE DE60209251T patent/DE60209251T2/de not_active Expired - Lifetime
- 2002-11-26 CA CA2468681A patent/CA2468681C/en not_active Expired - Fee Related
- 2002-11-26 AU AU2002346572A patent/AU2002346572A1/en not_active Abandoned
- 2002-11-26 EP EP02784641A patent/EP1453835B1/de not_active Expired - Lifetime
- 2002-11-26 KR KR1020047008031A patent/KR20050044607A/ko not_active Application Discontinuation
- 2002-11-26 WO PCT/US2002/038134 patent/WO2003048164A2/en active IP Right Grant
- 2002-11-26 AT AT02784641T patent/ATE317844T1/de not_active IP Right Cessation
- 2002-11-26 US US10/304,504 patent/US7041666B2/en not_active Expired - Lifetime
- 2002-11-26 JP JP2003549354A patent/JP4284181B2/ja not_active Expired - Fee Related
- 2002-11-26 HU HU0402270A patent/HUP0402270A3/hu unknown
- 2002-11-26 CN CNA028239229A patent/CN1596258A/zh active Pending
- 2002-11-26 IL IL16157202A patent/IL161572A0/xx unknown
- 2002-11-26 ES ES02784641T patent/ES2258164T3/es not_active Expired - Lifetime
- 2002-11-26 MX MXPA04005156A patent/MXPA04005156A/es active IP Right Grant
-
2004
- 2004-05-27 ZA ZA200404160A patent/ZA200404160B/en unknown
- 2004-09-11 HK HK04106913A patent/HK1064100A1/xx not_active IP Right Cessation
-
2008
- 2008-06-04 JP JP2008147394A patent/JP2008303217A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200404160B (en) | 2005-04-08 |
| CN1596258A (zh) | 2005-03-16 |
| WO2003048164A2 (en) | 2003-06-12 |
| JP4284181B2 (ja) | 2009-06-24 |
| HK1064100A1 (en) | 2005-01-21 |
| WO2003048164A3 (en) | 2003-10-16 |
| US7041666B2 (en) | 2006-05-09 |
| IL161572A0 (en) | 2004-09-27 |
| JP2005511698A (ja) | 2005-04-28 |
| EP1453835A2 (de) | 2004-09-08 |
| AR038366A1 (es) | 2005-01-12 |
| CA2468681C (en) | 2011-01-25 |
| HUP0402270A2 (hu) | 2005-02-28 |
| MXPA04005156A (es) | 2004-08-11 |
| AU2002346572A1 (en) | 2003-06-17 |
| HUP0402270A3 (en) | 2008-09-29 |
| DE60209251T2 (de) | 2006-11-09 |
| US20030212080A1 (en) | 2003-11-13 |
| CA2468681A1 (en) | 2003-06-12 |
| KR20050044607A (ko) | 2005-05-12 |
| EP1453835B1 (de) | 2006-02-15 |
| ATE317844T1 (de) | 2006-03-15 |
| JP2008303217A (ja) | 2008-12-18 |
| ES2258164T3 (es) | 2006-08-16 |
| TW200300686A (en) | 2003-06-16 |
| PE20030739A1 (es) | 2003-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE317844T1 (de) | Adenosine a2a receptor antagonisten | |
| DK1283839T3 (da) | Adenosin A2a-receptorantagonister | |
| ATE453647T1 (de) | Adenosin a2a rezeptor antagonisten | |
| HUP0401925A3 (en) | A2b adenosine receptor antagonists | |
| PT1192169E (pt) | C-pirazoles agonistas do receptor a2a | |
| NO20032277L (no) | Aminotiazoler og deres anvendelse som adenosinreseptorantagonister | |
| CY2011002I1 (el) | N-πυρραζολικοι αγωνιστες του α2α υποδοχεα | |
| IS5706A (is) | Adenosín A3 viðtakastillar | |
| DE60219196D1 (de) | BICYCLISCHE Ä1,2,4ö-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN | |
| DK1446379T3 (da) | Arylanilin-beta2-adrenergiske receptoragonister | |
| IL175759A0 (en) | A2b adenosine receptor antagonists | |
| ATE432282T1 (de) | 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten | |
| NO20020979D0 (no) | Selektive A2B-adenosin reseptorantagonister | |
| ATE394402T1 (de) | Kondensierte purinderivate als a1- adenosinrezeptorantagonisten | |
| ATE338043T1 (de) | 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten | |
| EP1636230A4 (de) | A1-adenosinrezeptorantagonisten | |
| IS6818A (is) | Histamín viðtaka mótlyf | |
| ATE320254T1 (de) | Crf receptor antagonisten | |
| SI1444233T1 (sl) | Antagonisti adenozinskega receptorja A2B | |
| SE0003996D0 (sv) | Receptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |